Other studies reported that: miR520c could inhibit breast cancer EMT by targeting STAT3 [145]; miR-10b antagomirs inhibit metastasis in a mouse mammary tumor model [146]; and that miR200c expression significantly enhanced the chemosensitivity and decreased the metastatic potential of a p53(null) claudin-low tumor model [147], and restored trastuzumab sensitivity while suppressing invasion of breast cancer cells [148]. This evidence concerns the gene TP53 and breast cancer.